Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IGF2
REST API REST API
Homo sapiens
IGF2 is differentially expressed in 279 experiments: 163 organism parts: liver, placenta, ... (161 more);, 238 disease states: normal, prostate carcinoma, ... (236 more);, 83 cell types 346 cell lines 27 compound treatments and 69 other conditions.
Synonyms C11orf43, FLJ44734
Orthologs Igf2 (Mus musculus)   igf2b (Danio rerio)   IGF2_CHICK (Gallus gallus)   igf2a (Danio rerio)   IGF2_BOVIN (Bos taurus)   Igf2 (Rattus norvegicus)   igf2 (Xenopus laevis)   IGF2 (Canis familiaris)   XB-GENE-5807444 (Xenopus laevis)   (Compare orthologs)
Gene Ontology Term insulin-like growth factor receptor binding, positive regulation of cell division, glucose metabolic process, protein binding, regulation of transcription, DNA-dependent, positive regulation of catalytic activity, extracellular space, positive regulation of cell proliferation, insulin receptor binding, growth factor activity, extracellular region, insulin receptor signaling pathway, positive regulation of transcription from RNA polymerase II promoter, multicellular organismal development, hormone activity, carbohydrate metabolic process, response to drug, response to radiation, organ morphogenesis, response to nutrient levels, striated muscle cell differentiation, positive regulation of peptidyl-tyrosine phosphorylation, response to nicotine, receptor activator activity, exocrine pancreas development, osteoblast differentiation, ossification, positive regulation of glycogen biosynthetic process, regulation of gene expression by genetic imprinting, positive regulation of activated T cell proliferation, positive regulation of insulin receptor signaling pathway, skeletal system development, response to estradiol stimulus, positive regulation of MAPKKK cascade, positive regulation of protein kinase B signaling cascade, positive regulation of mitosis, protein serine/threonine kinase activator activity, positive regulation of protein phosphorylation, positive regulation of receptor activity, positive regulation of glycogen (starch) synthase activity, response to organic cyclic compound, positive regulation of protein serine/threonine kinase activity, positive regulation of steroid hormone biosynthetic process
InterPro Term Insulin_family, Insulin-like, IGF2_C, IGF2, Insulin-like_growth_factor
UniProt Accession C9JAF2, P01344, E3UN45, E3UN46
Gene-Disease Assocation INSULIN-LIKE GROWTH FACTOR II; IGF2, SILVER-RUSSELL SYNDROME; SRS
Search EB-eye ENSG00000167244
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-17189, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (33 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
MCF-7
2
E-GEOD-19639, E-GEOD-20081
T84
2
E-GEOD-1474, E-MTAB-37
SW480
1
2
E-MEXP-1014, E-MTAB-37, E-GEOD-2509
SKUT1
1
E-MTAB-37
340 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (41 experiments)

Factor Value U/D Experiments
plasma cell
2
E-GEOD-6691, E-MEXP-2360
2
E-TABM-130, E-TABM-145
fibroblast
2
E-MEXP-466, E-GEOD-3920
vascular smooth muscle cell
1
E-TABM-130
iPSC derived from hASC using minicircle reprogramming vector
1
E-GEOD-20033
immortalized cell culture
1
E-GEOD-14990
77 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (61 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
4
E-MTAB-62, E-MEXP-2034, E-GEOD-7307, E-GEOD-96, E-MEXP-1327 ... (5 experiments)
cervical carcinoma
3
E-MTAB-62, E-GEOD-5823, E-MTAB-37
dermatomyositis
2
E-GEOD-1551, E-MTAB-62
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
Burkitt's lymphoma
2
E-GEOD-96, E-MTAB-37
232 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5824, E-GEOD-3720, E-GEOD-5099, ... (18 experiments)

Factor Value U/D Experiments
none
1
4
E-GEOD-412, E-GEOD-5824, E-GEOD-4600, E-GEOD-6907, E-GEOD-2803 ... (5 experiments)
glutamine
2
E-MEXP-1335, E-MEXP-941
dimethyl sulfoxide
1
E-GEOD-5824
vanadium pentoxide
1
E-GEOD-5339
tretinoin
1
E-GEOD-5258
hepatitis C virus core protein
1
E-GEOD-2067
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-19246, E-GEOD-21589, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-GEOD-6236, ... (10 experiments)

Disease free interval dfi in months
studied in E-GEOD-22541

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-2509, E-TABM-147, E-GEOD-21138, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-20847, E-MTAB-108, E-MEXP-563 ... (5 experiments)

Genotype
studied in E-GEOD-2152, E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-215, E-GEOD-20504, E-MEXP-1446, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MEXP-2069, E-GEOD-1926, E-GEOD-10433, E-TABM-118, ... (32 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-TABM-130, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-3407, E-GEOD-4600, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-19330, E-GEOD-17204

RNAi
studied in E-MEXP-2115, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-19246, E-GEOD-19815

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-89, E-GEOD-3494, E-TABM-43, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.427 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM